WARREN, N.J. — August 19, 2025 — Leads & Copy — Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, highlighting improved operational efficiency. The company’s Form 10-Q has been filed with the Securities and Exchange Commission (SEC).
Loss from operations decreased to $5.4 million for the three months ended June 30, 2025, compared to $8.6 million for the same period in 2024. Net loss for the quarter was $5.5 million, compared to $9.7 million in Q2 2024.
Tevogen is building infrastructure, advancing AI, and expanding internal capabilities. The company maintains financing to support operations and growth plans and is establishing its own GMP manufacturing facility.
According to Ryan Saadi, MD, MPH, Founder and CEO of Tevogen, the company maintains access to sufficient capital to support its path to anticipated revenue by the end of 2026 and is exploring options to address the limited tradable float.
Full details are available on the Form 10-Q filed with the SEC.
Contact: Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Source: Tevogen Bio Holdings Inc.
